Evidence map›Paper›PMID 32235562›Full record

ArticleMolecules (Basel, Switzerland)2020

Polydopamine-Lysophosphatidate-Functionalised Titanium: A Novel Hybrid Surface Finish for Bone Regenerative Applications.

Fiona Baldwin, Tim J Craig, Anna I Shiel, Timothy Cox, Kyueui Lee, Jason P Mansell

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Fiona BaldwinDepartment of Applied Sciences, University of the West of England, Bristol BS16 1QY, UK.
Tim J CraigDepartment of Applied Sciences, University of the West of England, Bristol BS16 1QY, UK.
Anna I ShielDepartment of Applied Sciences, University of the West of England, Bristol BS16 1QY, UK.ORCID 0000-0003-0380-0700
Timothy CoxDepartment of Applied Sciences, University of the West of England, Bristol BS16 1QY, UK.
Kyueui LeeDepartment of Bioengineering, University of California, Berkeley, CA 94720, USA.ORCID 0000-0002-1622-8806
Jason P MansellDepartment of Applied Sciences, University of the West of England, Bristol BS16 1QY, UK.
University of the West of England · GBUniversity of California, Berkeley · US

Funding

Department of Health II-LA-0315-20004National Institute for Health Research II-LA-0315-20004
6 · The paper itself

Abstract

Aseptic loosening of total joint replacements (TJRs) continues to be the main cause of implant failures. The socioeconomic impact of surgical revisions is hugely significant; in the United Kingdom alone, it is estimated that £135m is spent annually on revision arthroplasties. Enhancing the longevity of titanium implants will help reduce the incidence and overall cost of failed devices. In realising the development of a superior titanium (Ti) technology, we took inspiration from the growing interest in reactive polydopamine thin films for biomaterial surface functionalisations. Adopting a "one-pot" approach, we exposed medical-grade titanium to a mildly alkaline solution of dopamine hydrochloride (DHC) supplemented with (3S)1-fluoro-3-hydroxy-4-(oleoyloxy)butyl-1-phosphonate (FHBP), a phosphatase-resistant analogue of lysophosphatidic acid (LPA). Importantly, LPA and selected LPA analogues like FHBP synergistically cooperate with calcitriol to promote human osteoblast formation and maturation. Herein, we provide evidence that simply immersing Ti in aqueous solutions of DHC-FHBP afforded a surface that was superior to FHBP-Ti at enhancing osteoblast maturation. The facile step we have taken to modify Ti and the biological performance of the final surface finish are appealing properties that may attract the attention of implant manufacturers in the future.

Indexed as

Coated Materials, BiocompatibleIndolesLysophospholipidsPolymersTitaniumBone RegenerationCell LineHumansOsteoblastsCoated Materials, BiocompatibleIndoleslysophosphatidic acidLysophospholipidspolydopaminePolymersTitaniumdifferentiationfunctionalisationlysophosphatidic acidosteoblastspolydopaminetitanium

Identifiers

PMID32235562
PMCPMC7180599
OpenAlexW3013461350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.